

Pharmatrends: Augentropfen in der Presbyopiebehandlung

Pause für die Lesebrille, aber keine Konkurrenz

LITERATUR

[1] Wolffsohn JS, Davies LN, Sheppard AL. New insights in presbyopia: impact of correction strategies. *BMJ open ophthalmology*. 2023;8.

[2] Singh M, Sinha BP, Dutta S, Deokar KK, Mishra D, Goswami K. A Systematic Review and Meta-Analysis on the Efficacy and Safety of Topical Pilocarpine 1.25% in Presbyopia Treatment. *Journal of current ophthalmology*. 2024;36:111–21.

[3] Wesemann W. Vuity-Augentropfen in den USA zugelassen: Eine ernstzunehmende Konkurrenz zur Lesebrille? In: *Deutsche Optiker Zeitung*. 2022;2:72–77.

[4] McKenna J. 2022 Ophthalmic Revenue Roundup for Regeneron, AbbVie, Novartis, Roche and Two Others. Available at: <https://www.market-scope.com/pages/news/6693/2022-ophthalmic-revenue-roundup-for-regeneron-abbvie-novartis-roche-and-two-others> [accessed 20 July 2025].

[5] Hutton D. FDA approves twice-daily dosing option for presbyopia eye drop treatment. Available at: <https://www.opthalmologytimes.com/view/fda-approves-twice-daily-dosing-option-for-presbyopia-eye-drop-treatment;2023> [accessed 20 July 2025].

[6] Stevenson S, Joy J. Orasis Pharmaceuticals' prescription pilocarpine hydrochloride ophthalmic solution 0.4% (Qlosi) for presbyopia available in the US. Available at: <https://www.optometrytimes.com/view/orasis-pharmaceuticals-prescription-pilocarpine-hydrochloride-ophthalmic-solution-0-4-qlosi-for-presbyopia-available-in-the-us;2025> [accessed 20 July 2025].

[7] Holland E, Karpecki P, Fingeret M et al. Efficacy and Safety of CSF-1 (0.4% Pilocarpine Hydrochloride) in Presbyopia: Pooled Results of the NEAR Phase 3 Randomized, Clinical Trials. *Clinical therapeutics*. 2024;46:104–13.

[8] LENZTherapeutics. LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials. Available at: <https://ir.lenz-tx.com/news-events/press-releases/detail/11/lenz-therapeutics-announces-positive-topline-data-from-phase-3-clarity-presbyopia-trials;2024> [accessed 20 July 2025].

[9] McCabe C. An Update on Brimochol PF: Visus Therapeutics continues toward bringing a presbyopia-correcting drop to market. Available at: <https://www.presbyopiaphysician.com/issues/2024/september/an-update-on-brimochol-pf;2024>.